549 related articles for article (PubMed ID: 16688858)
41. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Cao X; Clavijo C; Li X; Lin HH; Chen Y; Shih HM; Ann DK
Mol Cancer Ther; 2008 Apr; 7(4):923-34. PubMed ID: 18413806
[TBL] [Abstract][Full Text] [Related]
42. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.
Van Damme E; Laukens K; Dang TH; Van Ostade X
Int J Biol Sci; 2010 Jan; 6(1):51-67. PubMed ID: 20087442
[TBL] [Abstract][Full Text] [Related]
43. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha.
Dawlaty MM; Malureanu L; Jeganathan KB; Kao E; Sustmann C; Tahk S; Shuai K; Grosschedl R; van Deursen JM
Cell; 2008 Apr; 133(1):103-15. PubMed ID: 18394993
[TBL] [Abstract][Full Text] [Related]
44. Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation.
Erker Y; Neyret-Kahn H; Seeler JS; Dejean A; Atfi A; Levy L
Mol Cell Biol; 2013 Jun; 33(11):2163-77. PubMed ID: 23530056
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein.
Kang H; Kim ET; Lee HR; Park JJ; Go YY; Choi CY; Ahn JH
J Gen Virol; 2006 Aug; 87(Pt 8):2181-2190. PubMed ID: 16847114
[TBL] [Abstract][Full Text] [Related]
46. Opposing biological functions of the cytoplasm and nucleus DAXX modified by SUMO-2/3 in gastric cancer.
Chen C; Sun X; Xie W; Chen S; Hu Y; Xing D; Xu J; Chen X; Zhao Z; Han Z; Xue X; Shen X; Lin K
Cell Death Dis; 2020 Jul; 11(7):514. PubMed ID: 32641734
[TBL] [Abstract][Full Text] [Related]
47. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
48. The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.
Schilling EM; Scherer M; Reuter N; Schweininger J; Muller YA; Stamminger T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903803
[TBL] [Abstract][Full Text] [Related]
49. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies.
Pennella MA; Liu Y; Woo JL; Kim CA; Berk AJ
J Virol; 2010 Dec; 84(23):12210-25. PubMed ID: 20861261
[TBL] [Abstract][Full Text] [Related]
50. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex.
Matunis MJ; Wu J; Blobel G
J Cell Biol; 1998 Feb; 140(3):499-509. PubMed ID: 9456312
[TBL] [Abstract][Full Text] [Related]
51. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.
Geoffroy MC; Jaffray EG; Walker KJ; Hay RT
Mol Biol Cell; 2010 Dec; 21(23):4227-39. PubMed ID: 20943951
[TBL] [Abstract][Full Text] [Related]
52. SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death.
Renner F; Moreno R; Schmitz ML
Mol Cell; 2010 Feb; 37(4):503-15. PubMed ID: 20188669
[TBL] [Abstract][Full Text] [Related]
53. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
Müller S; Matunis MJ; Dejean A
EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
[TBL] [Abstract][Full Text] [Related]
54. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies.
Engelhardt OG; Ullrich E; Kochs G; Haller O
Exp Cell Res; 2001 Dec; 271(2):286-95. PubMed ID: 11716541
[TBL] [Abstract][Full Text] [Related]
55. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
56. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
57. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
58. SUMO-1 targets RanGAP1 to kinetochores and mitotic spindles.
Joseph J; Tan SH; Karpova TS; McNally JG; Dasso M
J Cell Biol; 2002 Feb; 156(4):595-602. PubMed ID: 11854305
[TBL] [Abstract][Full Text] [Related]
59. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
[TBL] [Abstract][Full Text] [Related]
60. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal.
Riley BE; Zoghbi HY; Orr HT
J Biol Chem; 2005 Jun; 280(23):21942-8. PubMed ID: 15824120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
